Adaptimmune Therapeutics plc (473A) — Strategic Asset Allocation Index
Adaptimmune Therapeutics plc (473A) has a Strategic Asset Allocation Index of 61.2% as of June 2023. Strategic assets (PP&E of €77.52 Million plus long-term investments of €-) total €77.52 Million, measured against net assets of €126.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Adaptimmune Therapeutics plc net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Adaptimmune Therapeutics plc Strategic Asset Allocation Index (2016–2022)
This chart shows how Adaptimmune Therapeutics plc's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 61.2%, representing strategic assets of €77.52 Million against net assets of €126.65 Million EUR. For live market cap and overall valuation, see Adaptimmune Therapeutics plc market capitalisation.
Annual Strategic Asset Allocation Index for Adaptimmune Therapeutics plc (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Adaptimmune Therapeutics plc from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Adaptimmune Therapeutics plc (473A) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 87.4% | €71.53 Million | €71.53 Million | €- | €81.88 Million | ▲ +62.4 pp |
| 2021 | 24.9% | €51.37 Million | €51.37 Million | €- | €205.96 Million | ▲ +11.3 pp |
| 2020 | 13.7% | €46.66 Million | €46.66 Million | €- | €341.23 Million | ▼ -28.3 pp |
| 2019 | 41.9% | €51.86 Million | €51.86 Million | €- | €123.64 Million | ▲ +27.3 pp |
| 2018 | 14.6% | €36.12 Million | €36.12 Million | €- | €246.88 Million | ▼ -5.4 pp |
| 2017 | 20.0% | €40.68 Million | €40.68 Million | €- | €202.98 Million | ▲ +3.2 pp |
| 2016 | 16.8% | €27.90 Million | €27.90 Million | €- | €166.14 Million | — |